Laura C Maclagan1, Colleen J Maxwell1,2, Sima Gandhi1, Jun Guan1, Chaim M Bell1,3,4, David B Hogan5, Nick Daneman1,3,6,7, Sudeep S Gill1,8,9, Andrew M Morris3,4, Lianne Jeffs7,10,11, Michael A Campitelli1, Dallas P Seitz1,12, Susan E Bronskill1,7,13. 1. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 2. School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada. 3. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Division of General Internal Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. 5. Divison of Geriatric Medicine, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 6. Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 7. Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 8. Division of Geriatric Medicine, Queen's University, Kingston, Ontario, Canada. 9. Providence Care Hospital, Kingston, Ontario, Canada. 10. Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada. 11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. 12. Division of Geriatric Psychiatry, Queen's University, Kingston, Ontario, Canada. 13. Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Abstract
BACKGROUND/ OBJECTIVES: To estimate the prevalence of potentially inappropriate medication (PIM) use among older adults with cognitive impairment or dementia prior to and following admission to nursing homes and in relation to frailty. DESIGN: Retrospective cohort study using health administrative databases. SETTING: Ontario, Canada. PARTICIPANTS: 41,351 individuals with cognitive impairment or dementia, aged 66+ years newly admitted to nursing home between 2011 and 2014. MEASUREMENTS: PIMs were defined with 2015 Beers Criteria and included antipsychotics, H2 -receptor antagonists, benzodiazepines, and drugs with strong anticholinergic properties. Medication information was obtained at nursing home admission and in the subsequent 180 days. Multivariable Cox proportional-hazards models were used to assess the impact of frailty status (determined by a 72-item frailty index) on the hazard of starting and discontinuing PIMs. RESULTS: At admission, 44% of residents with cognitive impairment or dementia were on a PIM and prevalence varied by frailty (38.7% non-frail, 42.8% pre-frail, and 48.1% frail, P < .001). Following admission, many residents discontinued PIMs (23.5% for antipsychotics, 49.3% benzodiazepines, 32.2% anticholinergics, and 30.9% H2 -receptor antagonists). However, PIMs were also introduced with 10.9% newly started on antipsychotics, benzodiazepines (10.1%), anticholinergics (6.6%), and H2 -receptor antagonists (1.2%). After adjustment for other characteristics, frail residents had a similar risk of PIM discontinuation as non-frail residents except for anticholinergics (HR = 1.21, 95% CI 1.06-1.39) but were more likely to be newly prescribed benzodiazepines (HR = 1.32, 95% CI 1.20-1.44), antipsychotics (HR = 1.36, 1.23-1.49), and anticholinergics (HR = 1.34, 95% CI 1.20-1.50). CONCLUSION: Many residents with cognitive impairment or dementia enter nursing homes on PIMs. PIMs are more likely to be started in frail individuals following admission. Interventions to support deprescribing of PIMs should be implemented targeting frail individuals during the transition to nursing home.
BACKGROUND/ OBJECTIVES: To estimate the prevalence of potentially inappropriate medication (PIM) use among older adults with cognitive impairment or dementia prior to and following admission to nursing homes and in relation to frailty. DESIGN: Retrospective cohort study using health administrative databases. SETTING: Ontario, Canada. PARTICIPANTS: 41,351 individuals with cognitive impairment or dementia, aged 66+ years newly admitted to nursing home between 2011 and 2014. MEASUREMENTS: PIMs were defined with 2015 Beers Criteria and included antipsychotics, H2 -receptor antagonists, benzodiazepines, and drugs with strong anticholinergic properties. Medication information was obtained at nursing home admission and in the subsequent 180 days. Multivariable Cox proportional-hazards models were used to assess the impact of frailty status (determined by a 72-item frailty index) on the hazard of starting and discontinuing PIMs. RESULTS: At admission, 44% of residents with cognitive impairment or dementia were on a PIM and prevalence varied by frailty (38.7% non-frail, 42.8% pre-frail, and 48.1% frail, P < .001). Following admission, many residents discontinued PIMs (23.5% for antipsychotics, 49.3% benzodiazepines, 32.2% anticholinergics, and 30.9% H2 -receptor antagonists). However, PIMs were also introduced with 10.9% newly started on antipsychotics, benzodiazepines (10.1%), anticholinergics (6.6%), and H2 -receptor antagonists (1.2%). After adjustment for other characteristics, frail residents had a similar risk of PIM discontinuation as non-frail residents except for anticholinergics (HR = 1.21, 95% CI 1.06-1.39) but were more likely to be newly prescribed benzodiazepines (HR = 1.32, 95% CI 1.20-1.44), antipsychotics (HR = 1.36, 1.23-1.49), and anticholinergics (HR = 1.34, 95% CI 1.20-1.50). CONCLUSION: Many residents with cognitive impairment or dementia enter nursing homes on PIMs. PIMs are more likely to be started in frail individuals following admission. Interventions to support deprescribing of PIMs should be implemented targeting frail individuals during the transition to nursing home.
Authors: Barbara Resnick; Elizabeth Galik; Marie Boltz; Sarah Holmes; Steven Fix; Erin Vigne; Shijun Zhu; Regina Lewis Journal: Consult Pharm Date: 2018-06-01
Authors: Michael A Campitelli; Colleen J Maxwell; Laura C Maclagan; Dennis T Ko; Chaim M Bell; Lianne Jeffs; Andrew M Morris; Kate L Lapane; Nick Daneman; Susan E Bronskill Journal: CMAJ Date: 2019-01-14 Impact factor: 8.262
Authors: Jessica E Lockery; Michael E Ernst; Jonathan C Broder; Suzanne G Orchard; Anne Murray; Mark R Nelson; Nigel P Stocks; Rory Wolfe; Christopher M Reid; Danny Liew; Robyn L Woods Journal: Pharmacotherapy Date: 2020-10 Impact factor: 4.705
Authors: Andrea Iaboni; Michael A Campitelli; Susan E Bronskill; Christina Diong; Matthew Kumar; Laura C Maclagan; Tara Gomes; Mina Tadrous; Colleen J Maxwell Journal: CMAJ Open Date: 2019-09-23
Authors: Emanuele Rocco Villani; Davide Liborio Vetrano; Rosa Liperoti; Katie Palmer; Michael Denkinger; Henriëtte G van der Roest; Roberto Bernabei; Graziano Onder Journal: Aging Clin Exp Res Date: 2021-02-15 Impact factor: 3.636
Authors: Alberto Pilotto; Carlo Custodero; Stefania Maggi; Maria Cristina Polidori; Nicola Veronese; Luigi Ferrucci Journal: Ageing Res Rev Date: 2020-03-21 Impact factor: 10.895
Authors: Barbara Resnick; Ann Kolanowski; Kimberly Van Haitsma; Elizabeth Galik; Marie Boltz; Jeanette Ellis; Liza Behrens; Karen Eshraghi; Shijun Zhu Journal: Clin Nurs Res Date: 2019-04-03 Impact factor: 2.075
Authors: Kieran L Quinn; Michael A Campitelli; Christina Diong; Nick Daneman; Nathan M Stall; Andrew M Morris; Allan S Detsky; Lianne Jeffs; Colleen J Maxwell; Chaim M Bell; Susan E Bronskill Journal: J Gen Intern Med Date: 2019-10-01 Impact factor: 5.128
Authors: Barbara Resnick; Marie Boltz; Elizabeth Galik; Sarah Holmes; Steven Fix; Shijun Zhu Journal: Res Gerontol Nurs Date: 2019-10-04 Impact factor: 1.571